CRISPR Therapeutics Advances Gene-Editing Platform for Serious Diseases
CRISPR Therapeutics AG, a gene-editing company, is actively developing gene-based medicines for a range of serious human diseases. The company utilizes its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform, a technology that allows for the precise alteration of specific sequences of genomic DNA. Their therapeutic programs span various disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo applications, and Type 1 diabetes. A key product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy designed to treat patients with transfusion-dependent beta-thalassemia, severe sickle cell disease (SCD), and other hemoglobinopathies. This therapy works by editing a patient's hematopoietic stem and progenitor cells to produce high levels of fetal hemoglobin in red blood cells. Additionally, CRISPR Therapeutics is developing CAR T cell therapies like CTX112 and CTX131 for oncology and autoimmune indications, as well as in v... 
